AMAG's Makena Fails Confirmatory Pre-Term Birth Study, But May Not Be Pulled From Market
Executive Summary
The company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.